A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee

Not Applicable

Completed

Conditions: Osteoarthritis, Knee

Interventions: Device: EUFLEXXA™
Device: placebo

Registration Number: NCT00379236

Lead Sponsor: Ferring Pharmaceuticals

Brief Summary: This multicenter, randomized, double-blind study will be performed in approximately 600 subjects with chronic idiopathic osteoarthritis (OA) of the knee. An open-label safety extension will follow.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 588

Inclusion Criteria

Chronic OA of target knee confirmed by ACR Criteria
Pain due to OA in target knee present for at least 6 months:

• Moderate to severe pain score of 41 mm to 90 mm recorded on a 100 mm VAS immediately following a 50-foot walk
A bilateral standing AP X-ray confirming OA of the target knee-obtained within a 6-month period prior to the Screening Visit-and a grade of 2 or 3 according to the Kellgren and Lawrence Grading Scale
Ability and willingness to use only acetaminophen as the analgesic (rescue) study medication
- The acetaminophen dose must not exceed 4 grams/day (4000 mg)
- If subject has known chronic liver disease, the maximum dose of acetaminophen must not exceed 2 grams/day (2000 mg)
- The subject must be willing and able to discontinue acetaminophen at least 24 hours prior to all study-specific visits
- The study specific acetaminophen provided will only be used for knee pain.
Ability to perform procedures required of the pain index evaluations (unassisted walking 50 feet on a flat surface and going up and down stairs).
Willingness and ability to complete efficacy and safety questionnaires and ability to read and understand study instructions
Signed study-specific Subject Informed Consent Form

Exclusion Criteria

Any major injury (including sports injuries) to the target knee within the 12 months prior to the Screening Visit
Any surgery to the target knee within the 12 months prior to the Screening Visit, or surgery to the contralateral knee or other weight-bearing joint if it will interfere with knee assessments
Prior articular procedures, such as transplants or ligament reconstruction to the target knee
Inflammatory arthropathies such as rheumatoid arthritis, lupus arthropathy, or psoriatic arthritis
Gout or calcium pyrophosphate (pseudogout) diseases that have flared within the previous 6 months prior to the Screening Visit
X-ray findings of acute fractures, severe loss of bone density, avascular necrosis, and/or severe bone or joint deformity in the target knee
Osteonecrosis of either knee
Fibromyalgia, pes anserine bursitis, lumbar radiculopathy, and/or neurogenic or vascular claudication
Significant anterior knee pain due to diagnosed isolated patella-femoral syndrome or chondromalacia in the target knee
Significant target knee joint infection or skin disorder/infection within the previous 6 months prior to study enrollment
Symptomatic OA of the hips, spine, or ankle, if it would interfere with the evaluation of the target knee
Known hypersensitivity to acetaminophen, EUFLEXXA™, or Phosphate buffered saline solution
Women of childbearing potential who are pregnant, nursing, or planning to become pregnant, and those who do not agree to remain on an acceptable method of birth control throughout the entire study period
Recurrent medical history of severe allergic or immune-mediated reactions or other immune disorders
Vascular insufficiency of lower limbs or peripheral neuropathy severe enough to interfere with the study evaluation
Current treatment or treatment within the previous 2 years prior to the Screening Visit for any malignancy unless specific written permission is provided by the Sponsor (excluding basal cell or squamous cell carcinoma of the skin)
Active liver disease based on liver profile of AST, ALT, and conjugated bilirubin >2 times the upper limit of normal
Renal insufficiency based on serum creatinine >2.0 mg/dL
Any clinically significant laboratory value based on clinical history that the Investigator feels may affect the study evaluation
Any intercurrent chronic disease or condition that may interfere with the completion of the 6-month (or 12-month) follow-up of the study, such as liver disease, severe coronary disease, drug abuse, disordered mental state, or other clinically significant condition
Current alcoholism, and/or any known current addiction to pain medications
Any clinically significant finding that would place the patient at health risk, impact the study, or affect the completion of the study
Any psychiatric illness that would prevent comprehension of the details and nature of the study
Participation in any experimental drug or device study within the 6 months prior to the Screening Visit

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
EUFLEXXA™ Double-blind	EUFLEXXA™	Each subject received 3 single-dose injections of EUFLEXXA™ into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
Placebo Double-blind	placebo	Each subject received 3 single-dose injections of placebo into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
EUFLEXXA™ Open Label	EUFLEXXA™	All patients who participated in the 26 week double-blind study (including participants randomized to the placebo treatment group) and elected to participate in the open label extension, received three injections of EUFLEXXA™ in the target knee. Injections were given once a week on weeks 26, 27 and 28.

Primary Outcome Measures

Name	Time	Method
Observed Pain Scores on 50-foot Walk Test During the Double-blind Study	Weeks 0, 26	The level of pain is estimated by the participant following a walk of 50 feet in length which is observed by the investigator. Pain estimates were evaluated on a 100 millimeter visual analog scale. A score of 0 millimeters means there was no pain observed; a score of 100 millimeters means extreme pain was observed.
Percent Change From Baseline in Observed Pain Scores on 50-foot Walk Test During the Double-blind Study	Weeks 0 and 26	The percent difference in participant pain recorded by the participant during a walk of 50 feet in length between the baseline (week 0) and week 26 scores. Scores are measured on a visual analog scale of 100 millimeters; a score of 0 millimeters meaning no pain was observed; a score of 100 millimeters meaning extreme pain was observed.
Shifts From Extension Study Baseline (Week 26) in Range of Motion Findings at Week 52	weeks 26 and 52	Number of participants in various categories of target knee joint examination findings from baseline (week 26 pre-injection) to week 52. Range of motion indicates the flexibility of the knee, and is measured by the number of degrees between when the knee is hyper-extended and when the knee is flexed.
Shifts From Extension Study Baseline (Week 26) in Ratings of Knee Tenderness at Week 52	weeks 26 and 52	Number of participants in various categories of target knee joint examination findings from baseline (week 26 pre-injection) to week 52. Tenderness of the knee was subjectively rated by participants as none, mild, moderate or severe.
Shifts From Extension Study Baseline (Week 26) in Ratings of Knee Local Warmth at Week 52	weeks 26 and 52	Number of participants in various categories of target knee joint examination findings from baseline (week 26 pre-injection) to week 52. Local warmth of the target knee was recorded as Yes (warmth present) or No (knee was not warmer than expected).
Shifts From Extension Study Baseline (Week 26) in Ratings of Knee Redness at Week 52	weeks 26 and 52	Number of participants in various categories of target knee joint examination findings from baseline (week 26 pre-injection) to week 52. Redness of the knee was subjectively rated as Yes (knee was red) and No (knee was not red).

Secondary Outcome Measures

Name	Time	Method
Percent Change From Screening in Observed Pain Scores on 50-foot Walk Test During the Double-blind Study	weeks -1 and 26	The percent difference in participant pain recorded by the participant during a walk of 50 feet in length between the screening (week -1) and week 26 scores. Scores are measured on a visual analog scale of 100 millimeters; a score of 0 millimeters means there was no pain observed; a score of 100 millimeters means extreme pain was observed.
Percent Change From Baseline in Observed Pain Scores on 50-foot Walk Test During the Double-blind Study for a Subpopulation of Participants With More Severe Knee Pain	weeks -1, 0, and 26	Percent difference in participant pain during a walk of 50 feet in length between the mean screening (week -1) and baseline(week 0) scores, and week 26 scores. Scores are recorded by participants and measured on a visual analog scale of 100 millimeters, with 0 millimeters meaning there was no pain observed; 100 millimeters meaning extreme pain was observed.
Number of Observed Osteoarthritis Research Society International (OARSI30) Responders Using the 50-Foot Walk Test at Week 12	Week 12	Responders are identified based on a calculation of three scales: 50-foot walk test for pain, function and global assessment scales. Each of the individual scales was completed by the participant. A participant was a responder (answer: YES) if there was high improvement in pain or function (\>=50 percent and absolute change of \>=20 millimeters), or improvement in at least two of three categories: Pain and/or Function and/or Patient Global Assessment scales of \>=20 percent and absolute change \>=10 millimeter.
Number of Observed Osteoarthritis Research Society International (OARSI30) Responders Using the 50-Foot Walk Test at Week 26	Week 26	Responders are identified based on a calculation of three scales: 50-foot walk test for pain, function and global assessment scales. Each of the individual scales was completed by the participant. A participant was a responder (answer: YES) if there was high improvement in pain or function (\>=50 percent and absolute change of \>=20 millimeters), or improvement in at least two of three categories: Pain and/or Function and/or Patient Global Assessment scales of \>=20 percent and absolute change \>=10 millimeter.
Number of Observed Osteoarthritis Research Society International (OARSI30) Responders Using the Western Ontario McMaster University Osteoarthritis Index (WOMAC A) Pain Scale at Week 12	Week 12	Responders are identified based on a calculation of three scales: WOMAC (A) pain, function and global assessment scales. Each of the individual scales was completed by the participant. A participant was a responder (answer: YES) if there was high improvement in pain or function (\>=50 percent and absolute change of \>=20 millimeters), or improvement in at least two of three categories: Pain and/or Function and/or Patient Global Assessment scales of \>=20 percent and absolute change \>=10 millimeter.
Number of Observed Osteoarthritis Research Society International (OARSI30) Responders Using the Western Ontario McMaster University Osteoarthritis Index (WOMAC A) Pain Scale at Week 26	week 26	Responders are identified based on a calculation of three scales: WOMAC (A) pain, function and global assessment scales. Each of the individual scales was completed by the participant. A participant was a responder (answer: YES) if there was high improvement in pain or function (\>=50 percent and absolute change of \>=20 millimeters), or improvement in at least two of three categories: Pain and/or Function and/or Patient Global Assessment scales of \>=20 percent and absolute change \>=10 millimeter.
Change From Baseline in Patient Global Assessment of Knee Pain at Week 26	Weeks 0 and 26	Participant assessment of knee pain evaluated on a 100 millimeter visual analog scale. A score of 0 millimeters means there was no pain; a score of 100 millimeters means extreme pain.
Change From Baseline in the Number of Tablets of Rescue Medication Used at Week 26.	Weeks 0 and 26	The change in the number of tablets of 500 milligram acetaminophen used in a week as rescue medication is compared at weeks 0 and weeks 26.
Mean Change From Baseline in Short Form 36 Questionnaire (SF-36) Physical Function (PF) Score at Week 26	Weeks 0, 26	The SF-36 questionnaire yields a score for each domain of health. All domains are scored on a scale from 0 (negative health) to 100 (positive health), with 100 representing the best possible health state. This table summarizes the change from baseline in participants' physical function. The questionnaire is completed by participants.
Mean Change From Baseline in Short Form 36 Questionnaire (SF-36) Bodily Pain(BP) Score at Week 26	weeks 0 and 26	The SF-36 questionnaire yields a score for each domain of health. All domains are scored on a scale from 0 (negative health) to 100 (positive health), with 100 representing the best possible health state. This table summarizes the change from baseline in participants' bodily pain scores. The questionnaire is completed by participants.
Mean Change From Baseline in Short Form 36 Questionnaire (SF-36) General Health(GH) Score at Week 26	weeks 0 and 26	The SF-36 questionnaire yields a score for each domain of health. All domains are scored on a scale from 0 (negative health) to 100 (positive health), with 100 representing the best possible health state. This table summarizes the change from baseline in participants' general health scores. The questionnaire is completed by participants.
Mean Change From Baseline in Short Form 36 Questionnaire (SF-36) Physical Component Summary (PCS) Score at Week 26	Weeks 0, 26	The SF-36 questionnaire yields a score for each domain of health. All domains are scored on a scale from 0 (negative health) to 100 (positive health), with 100 representing the best possible health state. The questionnaire is completed by participants. This table summarizes the change from baseline in participants' physical health.
Number of Participants With 20 Millimeter or Greater Improvement in Pain Scores on the 50-foot Walk Test	Weeks 0 and 26	Yes represents the number of participants whose pain during a walk of 50 feet in length was improved at week 26 over baseline by at least 20 millimeters. Pain was evaluated on a 100 millimeter visual analog scale by participants. A score of 0 millimeters means there was no pain observed; a score of 100 millimeters means extreme pain was observed.
Observed Pain Scores on the 50-foot Walk Test During the Extension Study	Baseline (week 26), week 52	Participant pain during a walk of 50 feet in length was evaluated by participants on a 100 millimeter visual analog scale. A score of 0 millimeters means there was no pain observed; a score of 100 millimeters means extreme pain was observed.
Mean Change From Baseline in Observed Pain Scores on 50-foot Walk Test During the Extension Study	Extension baseline (week 26), week 52	The mean difference in participant pain as measured by participants during a walk of 50 feet in length between the baseline (week 26 pre-dose) and week 52 scores. Scores are measured on a visual analog scale of 100 millimeters, with a score of 0 millimeters meaning there was no pain observed; a score of 100 millimeters meaning extreme pain was observed.
Number of Observed Osteoarthritis Research Society International (OARSI30) Responders Using the 50-Foot Walk Test at Week 52	Week 52 (Extension Study)	Responders are identified based on a calculation of three scales: 50-foot walk test for pain, function and global assessment scales. Each of the individual scales was completed by the participant. A participant was a responder (answer:YES) if there was high improvement in pain or function (\>=50 percent and absolute change of \>=20 millimeters), or improvement in at least two of three categories: Pain and/or Function and/or Patient Global Assessment scales of \>=20 percent and absolute change \>=10 millimeter.
Change From Baseline (Extension Study Week 26) in Use of Rescue Medication at Week 52.	Extension baseline (week 26 pre-dose), week 52	The change in the number of tablets of study-specific acetaminophen taken per week as a rescue medication from knee pain.